A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

Running, not enrolling · Phase 2

Conditions studied: Pulmonary Arterial Hypertension

In brief

The purpose of this study to confirm the selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults doses in children from greater than or equal to (\>=) 2 to less than (˂) 18 years of age with Pulmonary Arterial Hypertension (PAH), by investigating the PK of selexipag and its active metabolite ACT-333679 in this population.

Key facts

Study ID

NCT03492177

Run by

Actelion

People needed

63

Starts

2018-07-23

Expected to finish

2026-12-31

Last updated by the study team

2026-07-06

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed and dated informed consent by the parent(s) or Legally authorized representative(s) AND assent from developmentally capable children
• Males or females between greater than or equal to (>=) 2 and less than (<) 18 years of age with weight >= 9 kilograms (kg)
• Pulmonary arterial hypertension (PAH) diagnosis confirmed by documented historical right heart catheterization (RHC) performed at any time before participant's enrollment
• PAH with one of the following etiologies:
• idiopathic (iPAH),
• heritable (hPAH),
• associated with congenital heart disease (CHD): PAH with co-incidental CHD; post-operative PAH (persisting/ recurring/ developing >= 6 months after repair of CHD)
• Drug or toxin-induced
• PAH associated with HIV
• PAH associated with connective tissue disease
• Word Health Organization functional class (WHO FC) II to III
• Participants treated with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor provided that the treatment dose(s) has been stable for at least 3 months prior to enrollment, or participants who are not candidates for these therapies
• Females of childbearing potential must have a negative pregnancy test at Screening and at Enrollment, and must agree to undertake monthly pregnancy tests, and to use a reliable method of contraception (if sexually active) from screening up to study drug discontinuation plus 30 days (EOS)
• Key Exclusion Criteria:
• Participants with PAH due to portal hypertension, schistosomiasis, pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis
• Participants with PAH associated with Eisenmenger syndrome
• Participants with moderate to large left-to-right shunts
• Participants with cyanotic congenital cardiac lesions such as transposition of the great arteries, truncus arteriosus, univentricular heart or pulmonary atresia with ventricular septal defect, as well as Participants with Fontan-palliation
• Participants with pulmonary hypertension due to lung disease
• Previous treatment with Uptravi (selexipag) within 2 weeks prior to enrollment
• Participants having received prostacyclin (epoprostenol) or prostacyclin analogs (that is, treprostinil, iloprost, beraprost) within 2 months prior to enrollment or are scheduled to receive any of these compounds during the trial
• Treatment with another investigational drug within 4 weeks prior to enrollment
• History, or current suspicion of intussusception or ileus or gastrointestinal obstruction as per investigator's judgment
• Uncontrolled thyroid disease as per investigator judgment
• Hemoglobin or hematocrit < 75 percentage (%) of the lower limit of normal range

Where it is running

• Children'S Hospital Cardiac Care Center University Of Colorado — Aurora, Colorado, United States
• University of Iowa Hospital — Iowa City, Iowa, United States
• Seattle Children's Hospital — Seattle, Washington, United States
• State Institution Republican Scientific And Practical Center For Pediatric Surgery — Minsk, Belarus
• Health Institution 4Th City Children'S Clinical Hospital — Minsk, Belarus
• UZ Gent — Ghent, Belgium
• Centre Hospitalier Sainte Justine — Montreal, Quebec, Canada
• Beijing Anzhen Hospital — Beijing, China
• Shanghai Childrens Medical Center — Shanghai, China
• CHU Arnaud de Villeneuve — Montpellier, France
• Hôpital Necker - Enfants Malades — Paris, France
• Chu Hopital Des Enfants — Toulouse, France
• Universitätsklinikum Freiburg Zentrum — Freiburg im Breisgau, Germany
• Gottsegen Gyorgy Orszagos Kardiologiai Intezet, Felnott kardiologiai osztaly — Budapest, Hungary
• Schneider Children's Medical Center — Petach Tikvah, Israel
• Sheba Medical Center — Ramat Gan, Israel
• Sarawak Heart Center — Kota Samarahan, Malaysia
• Institut Jantung Negara (National Heart Institute) — Kuala Lumpur, Malaysia
• Wojewodzki Szpital Specjalistyczny We Wroclawiu — Wroclaw, Poland
• Kazan State Medical University — Kazan', Russia
• Scientific and Research Institution of Cardiovascular Diseases Complex Problems — Kemerovo, Russia
• Moscow Scientific Research Institute For Pediatrics And Childrens Surgery Of Rosmedtechnologies — Moscow, Russia
• Saint Petersburg State Pediatric Medical University — Saint Petersburg, Russia
• Almazov National Medical Research Center Of The Ministry Of Health Of The Russian Federation — Saint Petersburg, Russia
• Samara Regional Clinical Cardiological Dispensary — Samara, Russia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.